|

CNP-106 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • COUR Pharmaceutical Development Company, Inc.1

Indications

  • MuSK MG1
  • AChR Myasthenia Gravis1
  • Generalized Myasthenia1
  • Myasthenia Gravis1
  • Cancer1

Phoenix, Arizona1 trial

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Barrow Neurological Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.